Tagged with

ANMAT ¿Cual fue la visión de la creación de ANMAT y las circunstancias de su creación? En el momento de la creación del ANMAT, el Gobierno Nacional entendió las necesidades de tener un organismo regulador fuerte para el país y tener una apertura económica y comercial mucho más amplia. El resultado…

Orion’s global strategy focuses on the CIS and Eastern European markets that still exhibit large growth potential and are expanding, despite a reverse trend for the rest of the industry. As the head for Ukraine and the CIS region, could you please tell our readers how Orion views this region…

Hungary With approximately $90 billion flowing into the country (according to the Hungarian Investment and Trade Agency) since it abolished its centrally planned economy and transformed into an open, pro-business economy in 1989, Hungary has been a leading destination for foreign direct investment (FDI) in Central and Eastern Europe (CEE). Together…

Sanofi Ukraine What were the factors that led to Sanofi’s decision to establish an LLC in 2009 in Ukraine, and how has it changed your operations? Most of the major foreign companies have an LLC now, for two key reasons. Firstly, it is risky to become too big and visible while continuing…

Erowlabs You have 25 years of experience in the Brazilian pharmaceutical industry, witnessing the major transformations of this market and the fast emergence of generics. Regarding your background and experience at Erowlabs, what were the main challenges you faced in order to establish the company in Brazil’s extremely competitive generics market?…

Ipsen Ukraine Ipsen has showed some very positive results worldwide in 2010 and so far this year, specifically in non-Western European markets that grew by 12% in 2010. How have the Ukrainian operations of Ipsen been faring in comparison to the global performance of the company? Let me first provide you a…

Sanofi SA Since we that came to South Africa in 2005 and interviewed you, what have been the main changes both in the market place, and within Sanofi as an organization? The healthcare market has seen a major shift in the way the pharmaceutical sector and the South African government engage with…

Astellas Ukraine Since the establishment of Astellas’ predecessor Brocade in Russia in 1992, what has been Astellas’ evolution in Ukraine? Astellas has been present in Ukraine for 16 years, first as Yamanouchi and then later as Astellas once the merger was complete. Since then, the company has been quite active with a…

Pharma Dynamics In 2005, when Focus Reports interviewed you, you were more towards the start up phase of Pharma Dynamics; and you have significantly grown in the market since then. What new dimension has Pharma Dynamics today in the South African pharma market, and how have you integrated the company’s growth in…

As the global economic roller coaster continues to unfold, governments the world over have desperately been scrambling to find the right policies that will effectively clamp on the brakes to end this unnerving joyride we have witnessed over the last few months, if not years. The frontline of this battle…

IMS Health South Africa Mrs. Reid, how would you define and describe the generic part of the South African pharmaceutical market? Linda Reid: South Africa is very much a branded generics market, and not a commodity generics market. The brand is important in South Africa and a lot of our generics are not International…

IMS Health South Africa Mr. Ehsan, you are the General Manager of IMS Africa since January 2010. What is the strategic importance of South Africa for IMS Global and for your personal country portfolio? For us, like many other multinationals (MNCs), South Africa remains a vibrant growth market. It is a country that we…